Grants and Contributions:
Title:
Development of a Low-Pass Whole-Genome Sequencing (LP-WGS) assay to detect circulating tumor deoxyribonucleic acid (ctDNA) changes over time
Agreement Number:
983833
Agreement Value:
$427,848.00
Agreement Date:
Dec 1, 2021 - Mar 31, 2023
Description:
Development of a Low-Pass Whole-Genome Sequencing (LP-WGS) assay to detect circulating tumor ribonucleic acid (ctDNA) changes over time.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6T 1Z3
Reference Number:
172-2021-2022-Q4-983833
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
832541841
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 243 days. The total amended value is 36,680 dollars.
Amendment Date
Dec 15, 2022
Recipient's Legal Name:
Canexia Health Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: